<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529564</url>
  </required_header>
  <id_info>
    <org_study_id>D4194R00023</org_study_id>
    <nct_id>NCT04529564</nct_id>
  </id_info>
  <brief_title>Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA).</brief_title>
  <official_title>First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First real-world data on unresectable stage III NSCLC patients treated with durvalumab after&#xD;
      chemoradiotherapy in Asia Area&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: The study is an observational review of medical records of patients diagnosed&#xD;
      with unresectable stage III NSCLC in South Korea and Taiwan, participating in an early access&#xD;
      program (EAP). Physicians having treated patients in the EAP will be asked to recruit these&#xD;
      patients to have their data abstracted from their medical records. Data will only be&#xD;
      collected from routine clinical care.&#xD;
&#xD;
      Data Source(s): Centre staff will extract de-identified data from patient's medical charts.&#xD;
      All collected data will be retrospective at time of extractions.&#xD;
&#xD;
      Study Population: Patients diagnosed with an unresectable stage III NSCLC, having not&#xD;
      progressed after a CRT and who have received at least one dose of durvalumab following the&#xD;
      CRT within the EAP will be the target population.&#xD;
&#xD;
      Exposure(s): Clinical characteristics, details of treatments (previous therapies, subsequent&#xD;
      therapies), durvalumab exposure and serious AESIs Primary Outcome(s): PFS and OS. Sample Size&#xD;
      Estimations: A target of 140 patients is estimated in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (estimate assessed up to 3 years)</time_frame>
    <description>Defined as the time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (including metastatic disease) determined by physicians' assessment, metastatic recurrence or death (if no progression) or end of follow-up (for censored observations)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>time from durvalumab initiation date up to death or last date the patient was known to be alive (estimate assessed up to 5 years)</time_frame>
    <description>Defined as the time from durvalumab initiation date up to death or last date the patient was known to be alive (for censored observations).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measures with retrospective collection of AESIs</measure>
    <time_frame>time from initiation of durvalumab therapy until stop treatment (assessed up to 3 years)</time_frame>
    <description>Require concomitant use of systemic corticoids, immunosuppressants and/or endocrine therapies, or&#xD;
Leading to durvalumab temporary interruption, or&#xD;
Leading to durvalumab permanent discontinuation.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>EAP patients</arm_group_label>
    <description>The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in South Korea and Taiwan during 2018 to 2019.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include all patients who have participated in the EAP between 1 September&#xD;
        2017 up to end of EAP enrolment (5 Nov 2018 for Taiwan and 31 Mar 2019 for South Korea) and&#xD;
        have received at least 1 dose of durvalumab prior to the study start. Patients may&#xD;
        participate in other clinical trials during this follow-up period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent or any locally required authorisation obtained from the&#xD;
             patient prior to performing any protocol-related procedures&#xD;
&#xD;
          2. Age ≥ 18 years (≥ 20 years for subjects in Taiwan) at time of study entry or adult&#xD;
             according to each country regulations for age of majority&#xD;
&#xD;
          3. Patients must have been enrolled in one of the Pacific durvalumab EAPs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients treated with durvalumab in clinical studies prior to the index date (first dose&#xD;
        of durvalumab received within the EAP)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Huggenberger</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Tsai, PhD</last_name>
    <phone>+886-2-27302303</phone>
    <email>jane.tsai@astrazeneca.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital-Hsinchu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen-Chung Ko</last_name>
      <email>e1205470@ms22.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin-Chou Wang</last_name>
      <email>ccwang52@adm.cgmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Keelung Branch</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Ke Kuo</last_name>
      <email>quaker777@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Te-Chun Hsia</last_name>
      <email>derrick.hsia@msa.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gee-Chen Chang</last_name>
      <email>cshy1888@csh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsung-Ying Yang</last_name>
      <email>jonyin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po Lan Su</last_name>
      <email>polan.750317@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Su</last_name>
      <email>jiansu@mmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao-Chi Ho</last_name>
      <email>ccho1203@ntu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Lu Chiang</last_name>
      <email>clchiang@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Liang Tsai</last_name>
      <email>doc10376@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Hsi Kuo</last_name>
      <email>chihhsikuo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

